Insulin modulates ischemia-induced endothelial progenitor cell mobilization and neovascularization in diabetic mice

Microvasc Res. 2011 Nov;82(3):227-36. doi: 10.1016/j.mvr.2011.09.006. Epub 2011 Sep 21.

Abstract

Decreased levels of circulating endothelial progenitor cells (EPCs) predict increased risk of cardiovascular events in diabetic patients. Insulin treatment exerts important cardiovascular protection. Whether and how insulin participates in the EPC regulation of postnatal neovascularization are currently unclear. We employed a mouse hindlimb ischemia model to study EPC mobilization in non-diabetic and streptozotocin-induced diabetic mice. Insulin was administered to diabetic animals postoperatively. To determine the role of EPCs contributing to postnatal vasculogenesis, we used bone marrow-transplanted mice whose bone marrow cells selectively expressed enhanced green fluorescent protein (EGFP). Insulin treatment improved EPC mobilization into peripheral blood, accelerated transcutaneous oxygen pressure restoration and increased capillary density in the ischemic limb associated with partial incorporation of EGFP-positive cells into the capillaries. Insulin treatment restored ischemia-induced release of stromal-derived growth factor 1α and vascular endothelial growth factor (VEGF), and consequently enhanced the activity of Akt and endothelial nitric oxide synthase (eNOS) as well as matrix metalloproteinase-9 in bone marrow. Insulin also augmented tissue-level activation of VEGF/Akt/eNOS pathway. However, all such effects of insulin were completely blocked by combined treatment with a NOS inhibitor. Our data suggested that insulin treatment improved ischemia-induced EPC mobilization and contributed to compensatory neovascularization in diabetic mice through a VEGF/eNOS-related pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Transplantation
  • Cell Movement / drug effects*
  • Chemokine CXCL12 / metabolism
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Experimental / physiopathology
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Endothelial Cells / transplantation
  • Enzyme Inhibitors / pharmacology
  • Green Fluorescent Proteins / biosynthesis
  • Green Fluorescent Proteins / genetics
  • Hindlimb
  • Hypoglycemic Agents / pharmacology*
  • Insulin / pharmacology*
  • Ischemia / complications
  • Ischemia / drug therapy*
  • Ischemia / pathology
  • Ischemia / physiopathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Muscle, Skeletal / blood supply*
  • Neovascularization, Physiologic / drug effects*
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Nitric Oxide Synthase Type III / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects
  • Stem Cell Transplantation
  • Stem Cells / drug effects*
  • Stem Cells / metabolism
  • Stem Cells / pathology
  • Time Factors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Chemokine CXCL12
  • Cxcl12 protein, mouse
  • Enzyme Inhibitors
  • Hypoglycemic Agents
  • Insulin
  • Vascular Endothelial Growth Factor A
  • enhanced green fluorescent protein
  • vascular endothelial growth factor A, mouse
  • Green Fluorescent Proteins
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Proto-Oncogene Proteins c-akt
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse